Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies

Authors
Publication date
6 September 2017
Publisher
Springer Science and Business Media LLC
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.1007%2Fs00262-017-...
      Last time updated on 27/03/2021